Company Ticker News March 7, 2022Bristol-Myers Squibb: Eliquis and Opdivo Are Shining Stars 0 0 Share
Press Release March 5, 2022U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer 0 0 Share
Company Ticker News March 4, 2022Alexandria (ARE) & Bristol Myers Boost Tie-Up With New Lease 0 0 Share
Press Release March 3, 2022Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers 0 0 Share
Press Release March 2, 2022Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers 0 0 Share
Press Release February 28, 2022U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer 0 0 Share
Press Release February 25, 2022Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1% 0 0 Share
